HSPD1 and cancer: In cancer cells, inhibitors of HSP60 such as Mizoribine and KIRA6 inhibit the activation of CXCL8, a pro-inflammatory chemokine, suggesting a role for HSP60 as an anti-inflammatory regulator in response to immunogens.